Ursodeoxycholic acid inhibits the uptake of cystine through SLC7A11 and impairs de novo synthesis of glutathione

• Published in: Journal of pharmaceutical analysis Vol. 15; no. 1; pp. 1 - 19
• Main Authors: Xie, Fu'an, Niu, Yujia, Chen, Xiaobing, Kong, Xu, Yan, Guangting, Zhuang, Aobo, Li, Xi, Lian, Lanlan, Qin, Dongmei, Zhang, Quan, Zhang, Ruyi, Yang, Kunrong, Xia, Xiaogang, Chen, Kun, Xiao, Mengmeng, Yangj, Chunkang, Wu, Ting, Shen, Ye, Yu, Chundong, Lin, Shu-Hai, Li, Wengang
• Format: Journal Article
• Language: English
• Published: Xi'an Xi'an Jiaotong University, Journal of Pharmaceutical Analysis 01.01.2025
• Subjects: Antitumor activity; Cancer therapies; Cell death; Cell proliferation; Chemotherapy; FDA approval; Ferroptosis; Glutaminase; Glutathione; Intestinal microflora; Kinases; Laboratory animals; Liposarcoma; MDM2 protein; Metabolites; Reactive oxygen species; Sarcoma; Toxicity; Tumors; Ursodeoxycholic acid
• ISSN: 2095-1779; 2214-0883
• DOI: 10.1016/jjpha.2024.101068

Ursodeoxycholic acid (UDCA) is a naturally occurring, low-toxicity, and hydrophilic bile acid (BA) in the human body that is converted by intestinal flora using primary BA. Solute carrier family 7 member 11 (SLC7A11) functions to uptake extracellular cystine in exchange for glutamate, and is highly expressed in a variety of human cancers. Retroperitoneal liposarcoma (RLPS) refers to liposarcoma originating from the retroperitoneal area. Lipidomics analysis revealed that UDCA was one of the most significantly down-regulated metabolites in sera of RLPS patients compared with healthy subjects. The augmentation of UDCA concentration (>25 ng/mL) demonstrated a suppressive effect on the proliferation of liposarcoma cells. [15N2]-cystine and [13C5]-glutamine isotope tracing revealed that UDCA impairs cystine uptake and glutathione (GSH) synthesis. Mechanistically, UDCA binds to the cystine transporter SLC7A11 to inhibit cystine uptake and impair GSH de novo synthesis, leading to reactive oxygen species (ROS) accumulation and mitochondrial oxidative damage. Furthermore, UDCA can promote the anti-cancer effects of ferroptosis inducers (Erastin, RSL3), the murine double minute 2 (MDM2) inhibitors (Nutlin 3a, RG7112), cyclin dependent kinase 4 (CDK4) inhibitor (Abemaciclib), and glutaminase inhibitor (CB839). Together, UDCA functions as a cystine exchange factor that binds to SLC7A11 for antitumor activity, and SLC7A11 is not only a new transporter for BA but also a clinically applicable target for UDCA. More importantly, in combination with other antitumor chemotherapy or physiotherapy treatments, UDCA may provide effective and promising treatment strategies for RLPS or other types of tumors in a ROS-dependent manner.